Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05057494 · ClinicalTrials.gov registry record · Phase 3
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3 study of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
- 20
- Study locations
NCT05057494: Active Phase 3 study of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, sponsored by AstraZeneca.
NCT05057494 is a Phase 3 study of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 607 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05057494, a Phase 3 study of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Primary Outcome
To assess whether minimal residual disease (MRD)-driven finite AV treatment is NI to MRD-driven finite VO treatment with respect to PFS. PFS is defined as the time from the date of randomization until date of objective progressive disease per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria as assessed by the investigator or death from any cause in the absence of progression.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Acalabrutinib
Study Locations (20)
New York
- Research Site - Buffalo
- Research Site - New Hyde Park
- Research Site - New York
- Research Site - Rochester
Washington
- Research Site - Seattle
- Research Site - Seattle
Arizona
- Research Site - Tucson
California
- Research Site - La Jolla
Colorado
- Research Site - Longmont
Florida
- Research Site - Jacksonville
Massachusetts
- Research Site - Boston
Missouri
- Research Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2029-04-10 |
| Phase | Phase 3 |
What the registry record for NCT05057494 still lists
NCT05057494 is an interventional study that assigns participants to a tested intervention. The registered 607 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT05057494 names 20 study sites across 16 states, led by New York, Washington, Arizona.
Frequently Asked Questions
What is clinical trial NCT05057494 about?
NCT05057494 is a clinical study titled "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
What is the current status of trial NCT05057494?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2022-09-12. Estimated completion is 2029-04-10.
What conditions does trial NCT05057494 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT05057494?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT05057494?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05057494 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05057494's enrollment target sits among peer trials
607 605th of 2000 higher than 1,396 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI